These studies point to the possible roles of the NLRP3 inflammasome in the pathogenesis of AD and offer the possibility of an NLRP3 inhibitor becoming a potential molecular target for improving AD-related symptoms and slowing AD progression at the neuroinflammatory level (Guan and Han, 2020). The gene discussed is NLRP3; the disease is Alzheimer disease.